{
  "meta": {
    "title": "Cancer_Therapy_-_Side_Effects",
    "url": "https://brainandscalpel.vercel.app/cancer-therapy-side-effects-a9df0a11.html",
    "scrapedAt": "2025-11-29T18:24:59.553Z"
  },
  "questions": [
    {
      "id": 19779,
      "choices": [
        {
          "id": 79077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone alone </span></span></span></p>"
        },
        {
          "id": 79078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5HT3 antagonist alone </span></span></span></p>"
        },
        {
          "id": 79079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist </span></span></span></p>"
        },
        {
          "id": 79080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient is about to start a chemotherapy regimen containing high-dose cyclophosphamide (&gt;1500mg/m&sup2;). Which antiemetic regimen is MOST appropriate for preventing CINV in this patient?</span></span></span></p>",
      "unique_key": "Q7302794",
      "question_audio": null,
      "question_video": null,
      "map_id": 19632,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose cyclophosphamide (&gt;1500mg/m<sup>2</sup>) as a high-risk emetogenic chemotherapy, requiring a combination of dexamethasone, a 5HT3 antagonist, and an NK1 receptor antagonist on days 1, 2, and 3 of the chemotherapy cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dexamethasone alone:</span></strong><span style=\"font-size:12.0pt\"> While dexamethasone has antiemetic properties, it is not sufficient on its own to prevent CINV in high-risk regimens like those involving high-dose cyclophosphamide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 5HT3 antagonist alone:</span></strong><span style=\"font-size:12.0pt\"> 5HT3 antagonists are effective antiemetics, but they are not potent enough to control CINV in high-risk settings when used alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dexamethasone + 5HT3 antagonist:</span></strong><span style=\"font-size:12.0pt\"> This combination provides better control than either drug alone, but it may still be inadequate for high-risk chemotherapy. The addition of an NK1 receptor antagonist further enhances antiemetic efficacy in these cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-risk emetogenic chemotherapy requires a triple-drug antiemetic regimen to effectively prevent CINV.</span></span></span></p>",
      "correct_choice_id": 79080,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19780,
      "choices": [
        {
          "id": 79081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loperamide </span></span></span></p>"
        },
        {
          "id": 79082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
        },
        {
          "id": 79083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ondansetron </span></span></span></p>"
        },
        {
          "id": 79084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Palifermin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman undergoing chemotherapy for ovarian cancer presents to your clinic with complaints of frequent, loose stools for the past 3 days. She reports having 5-6 bowel movements per day, with no blood or mucus. Her vital signs are stable, and she is otherwise feeling well. Which medication would be the MOST appropriate initial treatment for her chemotherapy-induced diarrhea?</span></span></p>",
      "unique_key": "Q5901195",
      "question_audio": null,
      "question_video": null,
      "map_id": 19633,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Loperamide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loperamide is an opioid receptor agonist that slows down gut motility. It is the first-line treatment for most cases of chemotherapy-induced diarrhea.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Octreotide:</span></strong><span style=\"font-size:12.0pt\"> Octreotide is a somatostatin analog that can be used for refractory cases of chemotherapy-induced diarrhea, particularly if there is a secretory component. It is not the initial drug of choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ondansetron:</span></strong><span style=\"font-size:12.0pt\"> Ondansetron is a 5-HT3 receptor antagonist primarily used for nausea and vomiting. It is not effective for diarrhea.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Racicodotril: </span></strong><span style=\"font-size:12.0pt\">Racicodotril is an antisecretory anti-diarrheal agent that works by inhibiting enkephalinase, an enzyme that breaks down enkephalins. Enkephalins are naturally occurring substances that decrease intestinal secretion. While it can be effective in some cases of diarrhoea, it is not the first-line treatment for chemotherapy-induced diarrhoea. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loperamide is the first-line treatment for chemotherapy-induced diarrhoea. It acts by slowing down gut motility and reducing the frequency of bowel movements.</span></span></p>",
      "correct_choice_id": 79081,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19781,
      "choices": [
        {
          "id": 79085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia. </span></span></span></p>"
        },
        {
          "id": 79086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a history of febrile neutropenia from prior chemotherapy. </span></span></span></p>"
        },
        {
          "id": 79087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment. </span></span></span></p>"
        },
        {
          "id": 79088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You are seeing a 60-year-old woman with newly diagnosed breast cancer scheduled to start chemotherapy with a regimen known to have a high risk of causing neutropenia. In which of the following scenarios is the use of G-CSF therapy MOST strongly indicated for this patient?</span></span></span></p>",
      "unique_key": "Q9220134",
      "question_audio": null,
      "question_video": null,
      "map_id": 19634,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) She has a history of febrile neutropenia from prior chemotherapy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A history of febrile neutropenia is a strong indication for primary prophylaxis with G-CSF, even if the current chemotherapy regimen is not considered high-risk. G-CSF stimulates the production of neutrophils, reducing the risk of severe neutropenia and subsequent infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.</span></strong><span style=\"font-size:12.0pt\"> While this is a moderate risk, it&#39;s not high enough to warrant primary prophylaxis with G-CSF in the absence of other risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment.</span></strong><span style=\"font-size:12.0pt\"> This scenario indicates the patient has already developed febrile neutropenia. G-CSF would be used for secondary prophylaxis in this case, not primary prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></strong><span style=\"font-size:12.0pt\"> Radiation therapy to the chest wall can sometimes cause a decrease in blood counts, but it&#39;s not a primary indication for G-CSF prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of febrile neutropenia is a strong indication for G-CSF prophylaxis, even if the current chemotherapy regimen is not considered high-risk. This is because patients who have experienced febrile neutropenia in the past are at a significantly higher risk of developing it again with subsequent chemotherapy. </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Use if FN risk &ge; 20%, H/o Febrile Neutropenia, Neutropenia prior to starting chemo or active infection while starting chemo. </span></span></p>",
      "correct_choice_id": 79086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19782,
      "choices": [
        {
          "id": 79089,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To provide a site for repeated blood transfusions</span></span></span></p>"
        },
        {
          "id": 79090,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To deliver high-dose chemotherapy directly to the tumor</span></span></span></p>"
        },
        {
          "id": 79091,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To facilitate the continuous and safe administration of chemotherapy</span></span></span></p>"
        },
        {
          "id": 79092,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To monitor the progression of cancer through imaging</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the primary purpose of the instrument shown in the image?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-093031.jpg\" style=\"height:202px; width:350px\" /></span></span></span></p>",
      "unique_key": "Q8563523",
      "question_audio": null,
      "question_video": null,
      "map_id": 19635,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) To facilitate the continuous and safe administration of chemotherapy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a <strong>chemotherapy port</strong> or <strong>port-a-cath</strong>. It&#39;s a small medical device implanted under the skin, typically in the chest area. It has a catheter that leads to a large vein, allowing easy access for administering chemotherapy drugs, drawing blood samples, and giving other intravenous medications or fluids. It reduces the need for repeated needle sticks, which can be painful and damage veins over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. To provide a site for repeated blood transfusions:</span></strong><span style=\"font-size:12.0pt\"> While a port can be used for blood transfusions, its primary function is for chemotherapy administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. To deliver high-dose chemotherapy directly to the tumor:</span></strong><span style=\"font-size:12.0pt\"> Ports deliver chemotherapy systemically, not directly to the tumor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. To monitor the progression of cancer through imaging:</span></strong><span style=\"font-size:12.0pt\"> Ports are not used for imaging or monitoring cancer progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chemotherapy ports are implanted devices that provide convenient and safe access to the bloodstream for patients undergoing long-term chemotherapy or other intravenous treatments.</span></span></span></p>",
      "correct_choice_id": 79091,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19852,
      "choices": [
        {
          "id": 79369,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rash </span></span></span></p>"
        },
        {
          "id": 79370,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">pneumonitis</span></span></span></p>"
        },
        {
          "id": 79371,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colitis </span></span></span></p>"
        },
        {
          "id": 79372,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the MOST common adverse drug reaction (ADR) associated with immune checkpoint inhibitors, as indicated in the image?</span></span></span></p>",
      "unique_key": "Q9931349",
      "question_audio": null,
      "question_video": null,
      "map_id": 19805,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Rash</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image lists rash as the most common ADR, occurring more frequently than the other listed side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pneumonitis: </span></strong><span style=\"font-size:12.0pt\">While pneumonitis (inflammation of the lungs) is a serious potential side effect of immune checkpoint inhibitors, it&#39;s not as frequent as rash<strong>.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Colitis: </span></strong><span style=\"font-size:12.0pt\">Colitis (inflammation of the colon) is another immune-related adverse event, but it&#39;s also less common than rash.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hepatitis: </span></strong><span style=\"font-size:12.0pt\">Hepatitis (inflammation of the liver) can occur with immune checkpoint inhibitors, but it&#39;s less frequent compared to rash.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key point: </span></strong><span style=\"font-size:12.0pt\">Rash is the most common adverse event associated with immune checkpoint inhibitors, although other serious immune-related adverse events can occur and require vigilant monitoring<strong>.</strong></span></span></span></p>",
      "correct_choice_id": 79369,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19847,
      "choices": [
        {
          "id": 79349,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary function tests </span></span></span></p>"
        },
        {
          "id": 79350,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram </span></span></span></p>"
        },
        {
          "id": 79351,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal ultrasound </span></span></span></p>"
        },
        {
          "id": 79352,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver function tests</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old woman with breast cancer is scheduled to begin a chemotherapy regimen including doxorubicin. Which of the following pre-treatment evaluations is MOST essential for this patient? </span></span></p>",
      "unique_key": "Q9393193",
      "question_audio": null,
      "question_video": null,
      "map_id": 19800,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Echocardiogram</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines, like doxorubicin, have a risk of dose-dependent cardiomyopathy. An echocardiogram is crucial to assess baseline cardiac function before starting treatment, allowing for early detection of any cardiac abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: &nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pulmonary function tests (PFTs):</span></strong><span style=\"font-size:12.0pt\"> PFTs assess lung function and are not directly relevant to the primary concern of cardiotoxicity associated with doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Renal ultrasound:</span></strong><span style=\"font-size:12.0pt\"> While some chemotherapy drugs can affect kidney function, it&#39;s not the primary concern with doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Liver function tests:</span></strong><span style=\"font-size:12.0pt\"> Liver function tests are important for evaluating the liver&#39;s ability to metabolize medications, but doxorubicin&#39;s primary toxicity is cardiac, not hepatic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Baseline cardiac evaluation with an echocardiogram is essential before starting anthracycline-based chemotherapy.</span></span></span></p>",
      "correct_choice_id": 79350,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19848,
      "choices": [
        {
          "id": 79353,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemorrhagic cystitis </span></span></span></p>"
        },
        {
          "id": 79354,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hemorrhage </span></span></span></p>"
        },
        {
          "id": 79355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiomyopathy </span></span></span></p>"
        },
        {
          "id": 79356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corneal opacity</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old man with a history of heavy smoking is diagnosed with squamous cell lung cancer. He is started on chemotherapy with carboplatin and paclitaxel, along with bevacizumab, a targeted therapy. During his treatment, which of the following adverse events is his oncologist MOST concerned about monitoring for, given his specific cancer type and treatment regimen?</span></span></span></p>",
      "unique_key": "Q5183462",
      "question_audio": null,
      "question_video": null,
      "map_id": 19801,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary hemorrhage</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bevacizumab, an anti-angiogenic agent, is known to increase the risk of pulmonary hemorrhage, especially in patients with squamous cell lung cancer. This is because squamous cell carcinomas tend to be more vascular and fragile, making them prone to bleeding when angiogenesis is disrupted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemorrhagic cystitis:</span></strong><span style=\"font-size:12.0pt\"> This is a potential side effect of certain chemotherapy drugs, like cyclophosphamide, but not typically associated with bevacizumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardiomyopathy:</span></strong><span style=\"font-size:12.0pt\"> While some chemotherapy drugs can cause cardiotoxicity, it&#39;s not a major concern with bevacizumab. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Corneal opacity</span></strong><span style=\"font-size:12.0pt\">: Corneal opacity is not a recognized side effect of bevacizumab or the other drugs in this regimen. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bevacizumab, while effective in treating various cancers, carries a risk of pulmonary hemorrhage, particularly in patients with squamous cell lung cancer. Close monitoring for any signs of respiratory distress or bleeding is essential in these patients.</span></span></p>",
      "correct_choice_id": 79354,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19849,
      "choices": [
        {
          "id": 79357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna </span></span></span></p>"
        },
        {
          "id": 79358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone </span></span></span></p>"
        },
        {
          "id": 79359,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ondansetron </span></span></span></p>"
        },
        {
          "id": 79360,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allopurinol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy with cyclophosphamide. During her second cycle, she complains of burning sensation while urinating and notices blood in her urine. You suspect a complication due to chemotherapy. Which of the following medications is MOST likely to prevent this complication?</span></span></span></p>",
      "unique_key": "Q4316952",
      "question_audio": null,
      "question_video": null,
      "map_id": 19802,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Mesna</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Cyclophosphamide is metabolized to acrolein, a toxic compound that can damage the bladder lining, leading to hemorrhagic cystitis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is a uroprotectant agent that specifically binds to acrolein in the bladder, neutralizing its toxic effects and preventing hemorrhagic cystitis.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dexamethasone:</span></strong><span style=\"font-size:12.0pt\"> A corticosteroid used to manage nausea and vomiting associated with chemotherapy; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ondansetron:</span></strong><span style=\"font-size:12.0pt\"> A 5-HT3 receptor antagonist used to manage nausea and vomiting; it&#39;s not effective for preventing hemorrhagic cystitis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Allopurinol:</span></strong><span style=\"font-size:12.0pt\"> A medication used to reduce uric acid levels, often in the context of tumor lysis syndrome; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is the standard preventive agent for hemorrhagic cystitis associated with cyclophosphamide. It should be administered concurrently with cyclophosphamide to minimize bladder toxicity.</span></span></span></p>",
      "correct_choice_id": 79357,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19850,
      "choices": [
        {
          "id": 79361,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytarabine </span></span></span></p>"
        },
        {
          "id": 79362,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ifosfamide </span></span></span></p>"
        },
        {
          "id": 79363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin </span></span></span></p>"
        },
        {
          "id": 79364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving chemotherapy develops a &quot;glove and stocking&quot; pattern of numbness and tingling in their hands and feet. Which of the following drugs is MOST likely responsible?</span></span></span></p>",
      "unique_key": "Q7378733",
      "question_audio": null,
      "question_video": null,
      "map_id": 19803,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cisplatin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image explicitly states that platinum-based drugs like cisplatin are associated with glove and stocking neuropathy (a type of peripheral neuropathy affecting the hands and feet) and ototoxicity (hearing loss).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cytarabine:</span></strong><span style=\"font-size:12.0pt\"> Cytarabine is primarily associated with cerebellar toxicity and myelosuppression. While it can rarely cause peripheral neuropathy, it is not typically characterized by a glove and stocking distribution.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ifosfamide:</span></strong><span style=\"font-size:12.0pt\"> Ifosfamide can cause hemorrhagic cystitis and neurotoxicity, but the characteristic glove and stocking neuropathy is less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gemcitabine:</span></strong><span style=\"font-size:12.0pt\"> Gemcitabine is associated with myelosuppression, flu-like symptoms, and rash. Peripheral neuropathy is not a typical side effect of this drug.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum-based chemotherapy agents carry the risk of peripheral neuropathy and ototoxicity.</span></span></span></p>",
      "correct_choice_id": 79363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19851,
      "choices": [
        {
          "id": 79365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hemorrhage </span></span></span></p>"
        },
        {
          "id": 79366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colitis </span></span></span></p>"
        },
        {
          "id": 79367,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pneumonitis </span></span></span></p>"
        },
        {
          "id": 79368,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving pembrolizumab develops new-onset cough and shortness of breath. Chest X-ray shows interstitial infiltrates. Which of the following adverse drug reactions (ADRs) is MOST likely?</span></span></span></p>",
      "unique_key": "Q8658265",
      "question_audio": null,
      "question_video": null,
      "map_id": 19804,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pneumonitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image lists pneumonitis as a potential ADR of PD-1 inhibitors like pembrolizumab. The patient&#39;s symptoms and imaging findings are consistent with this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pulmonary hemorrhage: </span></strong><span style=\"font-size:12.0pt\">While possible, pulmonary hemorrhage is less common than pneumonitis as an irAE of pembrolizumab. It would typically present with more dramatic symptoms like coughing up blood (hemoptysis).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colitis:</span></strong><span style=\"font-size:12.0pt\"> Colitis, or inflammation of the colon, can be an immune-related adverse event of checkpoint inhibitors. However, its primary symptoms would be diarrhea, abdominal pain, and possibly blood in the stool, not respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hepatitis:</span></strong><span style=\"font-size:12.0pt\"> Hepatitis, or inflammation of the liver, can also be an immune-related adverse event. Its typical presentation would involve jaundice, elevated liver enzymes, and possibly right upper quadrant pain, rather than respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune checkpoint inhibitors can cause immune-related adverse events, including pneumonitis, which requires prompt recognition and management.</span></span></span></p>",
      "correct_choice_id": 79367,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53420,
      "choices": [
        {
          "id": 213161,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor lysis syndrome </span></span></span></p>"
        },
        {
          "id": 213162,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine release syndrome (CRS) </span></span></span></p>"
        },
        {
          "id": 213163,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Graft-versus-host disease (GVHD) </span></span></span></p>"
        },
        {
          "id": 213164,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving CAR T-cell therapy develops fever, hypotension, and tachycardia two days after infusion. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
      "unique_key": "Q5227100",
      "question_audio": null,
      "question_video": null,
      "map_id": 25224,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Cytokine release syndrome (CRS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of fever, hypotension, and tachycardia shortly after CAR T-cell therapy is highly suggestive of CRS. This is due to the massive release of cytokines from activated T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tumor lysis syndrome:</span></strong><span style=\"font-size:12.0pt\"> While it can cause fever and electrolyte abnormalities, it&#39;s less likely to cause hypotension and tachycardia shortly after T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GVHD:</span></strong><span style=\"font-size:12.0pt\"> This occurs in allogeneic stem cell transplantation, not CAR T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sepsis:</span></strong><span style=\"font-size:12.0pt\"> Though sepsis can present similarly, the timing and context point more towards CRS in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CRS is a serious complication of CAR T-cell therapy characterized by a systemic inflammatory response due to cytokine release.</span></span></p>",
      "correct_choice_id": 213162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53421,
      "choices": [
        {
          "id": 213165,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache </span></span></span></p>"
        },
        {
          "id": 213166,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aphasia </span></span></span></p>"
        },
        {
          "id": 213167,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Delirium </span></span></span></p>"
        },
        {
          "id": 213168,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Optic neuritis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient receiving CAR T-cell therapy for refractory large B-cell lymphoma develops confusion, word-finding difficulty, and a severe headache three days after infusion. Which of the following neurological manifestations is LEAST likely to be associated with this patient&#39;s suspected diagnosis of Immune effector cell-associated neurotoxicity syndrome (ICANS)?</span></span></p>",
      "unique_key": "Q5315095",
      "question_audio": null,
      "question_video": null,
      "map_id": 25225,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Optic neuritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option E.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation is consistent with ICANS, a potential complication of CAR T-cell therapy characterized by a range of neurological symptoms. The most common manifestations include headache, encephalopathy (confusion, delirium), and aphasia (language impairment). Seizures can also occur, though less frequently.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Optic neuritis, or inflammation of the optic nerve, is not a typical feature of ICANS. It&#39;s more commonly associated with demyelinating diseases like multiple sclerosis. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Headache:</span></strong><span style=\"font-size:12.0pt\"> Headache is a very common symptom of ICANS, often presenting early in the course of the syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aphasia:</span></strong><span style=\"font-size:12.0pt\"> Aphasia, or difficulty with language, is another frequent manifestation of ICANS, reflecting the impact of cerebral edema on language centers in the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Delirium:</span></strong><span style=\"font-size:12.0pt\"> Delirium, or acute confusional state, is a hallmark of ICANS and can range from mild confusion to severe agitation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICANS is a serious complication of CAR T-cell therapy that can present with a variety of neurological symptoms. Recognizing these symptoms early is crucial for prompt management and improved patient outcomes. &nbsp;</span></span></span></p>",
      "correct_choice_id": 213168,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}